Do analysts rate ASND or TAK?

Ascendis Pharma A/S currently has a consensus target price of $295.39, suggesting a potential upside of 36.38%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 3.00 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer ASND or TAK?

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 2 mentions for Takeda Pharmaceutical. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Takeda Pharmaceutical's score of 1.09 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ARGX or ASND?

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 11.74 $1.29B $22.46 35.72 Ascendis Pharma A/S $814.57M 16.59 -$258M $8.67 24.98

Does the media refer more to ARGX or ASND?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than argenex. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for argenex. Ascendis Pharma A/S's average media sentiment score of 1.31 beat argenex's score of 0.58 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or ONC?

In the previous week, BeOne Medicines had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 12 mentions for BeOne Medicines and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.31 beat BeOne Medicines' score of 0.02 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RVMD or ASND?

In the previous week, Revolution Medicines had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 17 mentions for Revolution Medicines and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Revolution Medicines' score of 0.60 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ascendis Pharma A/S (ASND) Competitors

$216.60 -2.22 (-1.01%)

Closing price 06/2/2026 04:00 PM Eastern

Extended Trading

$215.49 -1.11 (-0.51%)

As of 09:29 AM Eastern

Compare

ASND vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy Ascendis Pharma A/S stock or one of its competitors? MarketBeat compares Ascendis Pharma A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascendis Pharma A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Ascendis Pharma A/S compare to Takeda Pharmaceutical?

Ascendis Pharma A/S (NASDAQ:ASND) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Ascendis Pharma A/S has a net margin of 57.87% compared to Takeda Pharmaceutical's net margin of 4.31%. Takeda Pharmaceutical's return on equity of 11.07% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 2 mentions for Takeda Pharmaceutical. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Takeda Pharmaceutical's score of 1.09 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.59	-$258M	$8.67	24.98
Takeda Pharmaceutical	$28.32B	1.71	$1.27B	$0.39	38.96

Ascendis Pharma A/S currently has a consensus target price of $295.39, suggesting a potential upside of 36.38%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Ascendis Pharma A/S beats Takeda Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to argenex?

argenex (NASDAQ:ARGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Ascendis Pharma A/S has a net margin of 57.87% compared to argenex's net margin of 31.31%. argenex's return on equity of 33.28% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.74	$1.29B	$22.46	35.72
Ascendis Pharma A/S	$814.57M	16.59	-$258M	$8.67	24.98

argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than argenex. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for argenex. Ascendis Pharma A/S's average media sentiment score of 1.31 beat argenex's score of 0.58 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex presently has a consensus price target of $1,019.50, suggesting a potential upside of 27.09%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 36.38%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

60.3% of argenex shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

argenex beats Ascendis Pharma A/S on 9 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Teva Pharmaceutical Industries?

Ascendis Pharma A/S (NASDAQ:ASND) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Ascendis Pharma A/S currently has a consensus price target of $295.39, suggesting a potential upside of 36.38%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 26.68%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ascendis Pharma A/S has a net margin of 57.87% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 10 mentions for Ascendis Pharma A/S. Teva Pharmaceutical Industries' average media sentiment score of 1.37 beat Ascendis Pharma A/S's score of 1.31 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Ascendis Pharma A/S. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.59	-$258M	$8.67	24.98
Teva Pharmaceutical Industries	$17.26B	2.20	$1.41B	$1.33	24.80

Summary

Ascendis Pharma A/S beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to BeOne Medicines?

Ascendis Pharma A/S (NASDAQ:ASND) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

BeOne Medicines has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.59	-$258M	$8.67	24.98
BeOne Medicines	$5.34B	5.64	$286.93M	$4.47	61.45

Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to BeOne Medicines' net margin of 8.94%. BeOne Medicines' return on equity of 12.06% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, BeOne Medicines had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 12 mentions for BeOne Medicines and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.31 beat BeOne Medicines' score of 0.02 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.6% of BeOne Medicines shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ascendis Pharma A/S presently has a consensus price target of $295.39, indicating a potential upside of 36.38%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 41.98%. Given BeOne Medicines' higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

BeOne Medicines beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Ascendis Pharma A/S has a net margin of 57.87% compared to Revolution Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Revolution Medicines presently has a consensus price target of $123.72, suggesting a potential downside of 18.23%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 36.38%. Given Ascendis Pharma A/S's higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

In the previous week, Revolution Medicines had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 17 mentions for Revolution Medicines and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Revolution Medicines' score of 0.60 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ascendis Pharma A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,777.94	-$1.13B	-$7.07	N/A
Ascendis Pharma A/S	$814.57M	16.59	-$258M	$8.67	24.98

Summary

Ascendis Pharma A/S beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASND vs. The Competition

Export

Metric	Ascendis Pharma A/S	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.65B	$3.32B	$6.32B	$12.58B
Dividend Yield	N/A	2.33%	2.69%	5.45%
P/E Ratio	24.98	17.44	21.04	24.56
Price / Sales	16.59	322.54	561.99	126.87
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	-72.93	6.50	9.83	6.75
Net Income	-$258M	$24.15M	$3.56B	$337.19M
7 Day Performance	-7.93%	-2.46%	-0.44%	1.88%
1 Month Performance	-1.96%	1.16%	4.58%	6.59%
1 Year Performance	24.20%	46.65%	27.58%	35.52%

Ascendis Pharma A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASND Ascendis Pharma A/S	4.6375 of 5 stars	$216.60 -1.0%	$295.39 +36.4%	+23.3%	$13.65B	$814.57M	24.98	1,189	Positive News Short Interest Decrease
TAK Takeda Pharmaceutical	3.6929 of 5 stars	$16.22 -0.2%	N/A	+0.8%	$51.71B	$28.32B	41.60	47,455
ARGX argenex	4.2117 of 5 stars	$806.46 flat	$1,017.78 +26.2%	+37.2%	$49.91B	$4.25B	35.91	1,863	Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.8968 of 5 stars	$34.04 -0.1%	$41.78 +22.7%	+91.1%	$39.17B	$17.26B	25.59	33,950	Positive News
ONC BeOne Medicines	4.4002 of 5 stars	$310.25 flat	$389.15 +25.4%	+11.7%	$34.04B	$5.34B	69.41	12,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASND) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Competitors

ASND vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Ascendis Pharma A/S compare to Takeda Pharmaceutical?

Summary

How does Ascendis Pharma A/S compare to argenex?

Summary

How does Ascendis Pharma A/S compare to Teva Pharmaceutical Industries?

Summary

How does Ascendis Pharma A/S compare to BeOne Medicines?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Competitors

ASND vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Ascendis Pharma A/S compare to Takeda Pharmaceutical?

Is ASND or TAK more profitable?

Which has more volatility and risk, ASND or TAK?

Do institutionals and insiders have more ownership in ASND or TAK?

Does the media prefer ASND or TAK?

Which has better valuation and earnings, ASND or TAK?

Do analysts rate ASND or TAK?

Summary

How does Ascendis Pharma A/S compare to argenex?

Is ARGX or ASND more profitable?

Which has stronger valuation & earnings, ARGX or ASND?

Which has more risk & volatility, ARGX or ASND?

Does the media refer more to ARGX or ASND?

Do analysts rate ARGX or ASND?

Do institutionals & insiders hold more shares of ARGX or ASND?

Summary

How does Ascendis Pharma A/S compare to Teva Pharmaceutical Industries?

Do analysts recommend ASND or TEVA?

Is ASND or TEVA more profitable?

Which has more risk & volatility, ASND or TEVA?

Does the media prefer ASND or TEVA?

Do institutionals and insiders have more ownership in ASND or TEVA?

Which has preferable valuation and earnings, ASND or TEVA?

Summary

How does Ascendis Pharma A/S compare to BeOne Medicines?

Which has preferable earnings and valuation, ASND or ONC?

Which has more risk & volatility, ASND or ONC?

Is ASND or ONC more profitable?

Does the media prefer ASND or ONC?

Do institutionals and insiders believe in ASND or ONC?

Do analysts prefer ASND or ONC?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Is RVMD or ASND more profitable?

Do analysts rate RVMD or ASND?

Which has more risk & volatility, RVMD or ASND?

Does the media favor RVMD or ASND?

Do insiders & institutionals hold more shares of RVMD or ASND?

Which has higher earnings & valuation, RVMD or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools